Document Detail


Tobacco industry lawyers as "disease vectors".
MedLine Citation:
PMID:  17652236     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Despite their obligation to do so, tobacco companies often failed to conduct product safety research or, when research was conducted, failed to disseminate the results to the medical community and to the public. The tobacco company lawyers' role in these actions was investigated with a focus on their involvement in company scientific research, claims of attorney-client privilege and work-product cover, document concealment, and litigation tactics. METHODS: Searches of previously secret internal tobacco industry documents located at Tobacco Documents Online. Additional searches included court transcripts, legal cases and articles obtained through Westlaw, PubMed, and the internet. RESULTS: Tobacco company lawyers have been involved in activities having little or nothing to do with the practice of law, including gauging and attempting to influence company scientists' beliefs, vetting in-house scientific research, and instructing in-house scientists not to publish potentially damaging results. Additionally, company lawyers have taken steps to manufacture attorney-client privilege and work-product cover to assist their clients in protecting sensitive documents from disclosure, have been involved in the concealment of such documents, and have employed litigation tactics that have largely prevented successful lawsuits against their client companies. CONCLUSIONS: Tobacco related diseases have proliferated partly because of tobacco company lawyers. Their tactics have impeded the flow of information about the dangers of smoking to the public and the medical community. Additionally, their extravagantly aggressive litigation tactics have pushed many plaintiffs into dropping their cases before trial, thus reducing the opportunities for changes to be made to company policy in favour of public health. Stricter professional oversight is needed to ensure that this trend does not continue.
Authors:
Sara D Guardino; Richard A Daynard
Related Documents :
18243586 - Location and longing: the nicotine craving experience in virtual reality.
11866166 - The drd4 vntr polymorphism influences reactivity to smoking cues.
16997146 - Regulating biopharmaceuticals under cder versus cber: an insider's perspective.
20017206 - The role of entrepreneurial activities in academic pharmaceutical science research.
20465076 - Patients' expressed and unexpressed needs for information for informed consent.
11728626 - Recruitment strategies in the asthma clinical research network.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Tobacco control     Volume:  16     ISSN:  1468-3318     ISO Abbreviation:  Tob Control     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-26     Completed Date:  2007-12-27     Revised Date:  2010-09-15    
Medline Journal Info:
Nlm Unique ID:  9209612     Medline TA:  Tob Control     Country:  England    
Other Details:
Languages:  eng     Pagination:  224-8     Citation Subset:  IM    
Affiliation:
Public Health Advocacy Institute, 102 The Fenway, Cushing Hall Suite 117, Boston, MA 02115, USA. saraguardino@phaionline.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biomedical Research / legislation & jurisprudence
Conflict of Interest
Consumer Product Safety
Humans
Lawyers / standards*
Professional Misconduct
Smoking / adverse effects,  legislation & jurisprudence
Tobacco Industry / legislation & jurisprudence*,  standards
Truth Disclosure
Grant Support
ID/Acronym/Agency:
1 R01 CA87571/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Venous ulcers of the lower limbs due to congenital thalidomide-related valve defect.
Next Document:  Second-hand tobacco smoke in public places in urban and rural China.